Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Irritable Bowel Syndrome
NCT06788444Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of esketamine in irritable bowel syndrome (IBS) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Irritable Bowel Syndrome Severity Scoring System at 6 weeks. Started Feb 2025; status: recruiting.
02
Drugs
esketamine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06788444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788444.